From HFSA 2025: The Latest in Managing Patients With HFrEF
Optimizing therapy for patients with heart failure with reduced ejection fraction is a critical component of their care. But HFrEF can be a challenging condition for patients, even with quadruple guideline-directed medical therapy (GDMT), and many can continue to face substantial residual risk. What can clinicians do to help their patients reach their treatment goals? Find out what the experts say about the latest data from HFSA 2025.
Episodes 1-4 of 4
Effect of Vericiguat on Heart Failure Hospitalization Events in Ambulatory Patients With HFrEF: VICTOR Trial Prespecified Analysis
CardiologyEffect of Vericiguat on Heart Failure Hospitalization Events in Ambulatory Patients With HFrEF: VICTOR Trial Prespecified Analysis
VICTOR Trial Results: Regional Variation in Outcomes and Response to Vericiguat in Patients With HFrEF
CardiologyVICTOR Trial Results: Regional Variation in Outcomes and Response to Vericiguat in Patients With HFrEF
VICTOR Prespecified Analysis Results: Vericiguat Effects on Mortality in Ambulatory Patients With HFrEF
CardiologyVICTOR Prespecified Analysis Results: Vericiguat Effects on Mortality in Ambulatory Patients With HFrEF
VICTOR Trial Results: Vericiguat Efficacy and Safety Across Baseline Background Therapy in Contemporary Ambulatory Patients With HFrEF
CardiologyVICTOR Trial Results: Vericiguat Efficacy and Safety Across Baseline Background Therapy in Contemporary Ambulatory Patients With HFrEF
- advertisement
